MX9205659A - Inhibidor del engrosamiento interno ateroesclerotico. - Google Patents

Inhibidor del engrosamiento interno ateroesclerotico.

Info

Publication number
MX9205659A
MX9205659A MX9205659A MX9205659A MX9205659A MX 9205659 A MX9205659 A MX 9205659A MX 9205659 A MX9205659 A MX 9205659A MX 9205659 A MX9205659 A MX 9205659A MX 9205659 A MX9205659 A MX 9205659A
Authority
MX
Mexico
Prior art keywords
alkyl
hydrogen
butoxy
chem
tert
Prior art date
Application number
MX9205659A
Other languages
English (en)
Inventor
Yasushi Saito
Masaki Kitahara
Mitsuaki Sakashita
Kyomi Toyoda
Toshie Shibazaki
Original Assignee
Nissan Chemical Ind Ltd
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Ind Ltd, Kowa Co filed Critical Nissan Chemical Ind Ltd
Publication of MX9205659A publication Critical patent/MX9205659A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX9205659A 1991-10-04 1992-10-02 Inhibidor del engrosamiento interno ateroesclerotico. MX9205659A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP03257870A JP3130342B2 (ja) 1991-10-04 1991-10-04 動脈硬化性血管内膜肥厚抑制薬

Publications (1)

Publication Number Publication Date
MX9205659A true MX9205659A (es) 1993-04-01

Family

ID=17312323

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9205659A MX9205659A (es) 1991-10-04 1992-10-02 Inhibidor del engrosamiento interno ateroesclerotico.

Country Status (18)

Country Link
US (1) US6162798A (es)
EP (1) EP0535548B1 (es)
JP (1) JP3130342B2 (es)
KR (1) KR100264543B1 (es)
AT (1) ATE209035T1 (es)
AU (1) AU652669B2 (es)
CA (1) CA2079706C (es)
CZ (1) CZ281786B6 (es)
DE (1) DE69232217T2 (es)
DK (1) DK0535548T3 (es)
HU (1) HU214624B (es)
MX (1) MX9205659A (es)
NO (1) NO302452B1 (es)
NZ (1) NZ244555A (es)
RU (1) RU2114620C1 (es)
SK (1) SK279277B6 (es)
TW (1) TW238300B (es)
UA (1) UA39095C2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011898A1 (en) * 1992-05-12 1995-05-04 Nissan Chemical Industries Ltd. Condensed pyridine type mevalonolactone intermediate and process for its production
ES2201266T3 (es) * 1996-01-17 2004-03-16 Taiho Pharmaceutical Company Limited Inhibidores del espesamiento de la capa intima.
NZ509401A (en) * 1998-07-23 2002-08-28 Nissan Chemical Ind Ltd Process for the preparation of quinoline derivative using the intermediate 2-cyclopropyl-3-(3-cyano-prop-2-ene)-4-(4-fluorophenyl)-quinoline
WO2000042016A1 (fr) * 1999-01-14 2000-07-20 Nissan Chemical Industries, Ltd. Fabrication de quinlinecarbaldéhyde
JP4496586B2 (ja) * 2000-01-24 2010-07-07 日産化学工業株式会社 キノリルアクリロニトリルの製造法及びその中間体
EP1251124B1 (en) * 2000-01-24 2007-07-04 Nissan Chemical Industries, Ltd. Process for the preparation of quinolylpropenal
JP4496585B2 (ja) * 2000-01-24 2010-07-07 日産化学工業株式会社 キノリルプロペナールの製造方法
JP4496584B2 (ja) * 2000-01-24 2010-07-07 日産化学工業株式会社 キノリルプロペナールの製造法
JP4867071B2 (ja) * 2000-02-21 2012-02-01 日産化学工業株式会社 キノリン誘導体の製造方法
US6855824B2 (en) 2000-02-21 2005-02-15 Kuraray Co., Ltd. Processes for preparing quinoline derivatives and intermediates thereof
AU2001264313A1 (en) * 2000-06-20 2002-01-02 Japan Tobacco Inc. Pyrazolopyridine compounds and use thereof as drugs
AU2003213682C1 (en) * 2002-03-04 2008-06-12 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin alphavbeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate
EP1568693A4 (en) * 2002-11-06 2007-09-05 Nissan Chemical Ind Ltd PROCESS FOR PRODUCING QUINOLINECARBALDEHYDE
CN100378077C (zh) * 2002-11-06 2008-04-02 日产化学工业株式会社 喹啉甲醛类的制造方法
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2005058834A2 (en) 2003-12-12 2005-06-30 Wyeth Quinolines useful in treating cardiovascular disease
KR20070042164A (ko) * 2004-07-05 2007-04-20 아스텔라스세이야쿠 가부시키가이샤 피라졸로피리딘 유도체
CN100445267C (zh) * 2005-10-21 2008-12-24 上海医药工业研究院 4-(4-氟-苯基)-3-羟甲基-2-环丙基-喹啉的制备方法
KR20150027267A (ko) 2012-06-29 2015-03-11 화이자 인코포레이티드 LRRK2 억제제로서의 4-(치환된-아미노)-7H-피롤로[2,3-d]피리미딘
CN103204807B (zh) * 2013-04-08 2015-12-23 黄河三角洲京博化工研究院有限公司 一种2-环丙基-4-(4-氟-苯基)-3-喹啉甲醛的合成方法
EP3081566B1 (en) * 2013-12-13 2018-03-07 Daiichi Sankyo Company, Limited 5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
CN104031034B (zh) * 2014-07-01 2017-01-04 上海信谊百路达药业有限公司 一种匹伐他汀钙原料药中间体的制备方法
MX2018003215A (es) 2015-09-14 2018-06-08 Pfizer Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336714C (en) * 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US4761419A (en) * 1987-12-07 1988-08-02 Warner-Lambert Company 6-(((substituted)quinolinyl)ethyl)-and ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4822799A (en) * 1988-01-27 1989-04-18 Sandoz Pharm. Corp. Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
JP2890448B2 (ja) * 1988-04-26 1999-05-17 日産化学工業株式会社 ピラゾロピリジン系メバロノラクトン類
US5024999A (en) * 1988-04-26 1991-06-18 Nissan Chemical Industries Ltd. Pyrazolopyridine type mevalonolactones useful as pharmaeuticals
US5026698A (en) * 1988-11-02 1991-06-25 Nissan Chemical Industries, Ltd. Thienopyridine type mevalonolactones

Also Published As

Publication number Publication date
CZ302792A3 (en) 1993-10-13
KR100264543B1 (ko) 2001-10-24
NO923858L (no) 1993-04-05
CA2079706C (en) 2004-03-30
HU214624B (hu) 1998-04-28
AU2601292A (en) 1993-04-08
UA39095C2 (uk) 2001-06-15
JP3130342B2 (ja) 2001-01-31
NZ244555A (en) 2000-06-23
CZ281786B6 (cs) 1997-01-15
DE69232217T2 (de) 2002-05-23
SK302792A3 (en) 1995-11-08
US6162798A (en) 2000-12-19
AU652669B2 (en) 1994-09-01
HUT62794A (en) 1993-06-28
TW238300B (es) 1995-01-11
DK0535548T3 (da) 2002-05-13
DE69232217D1 (de) 2002-01-03
EP0535548B1 (en) 2001-11-21
JPH06329540A (ja) 1994-11-29
RU2114620C1 (ru) 1998-07-10
SK279277B6 (sk) 1998-09-09
NO302452B1 (no) 1998-03-09
KR930007449A (ko) 1993-05-20
CA2079706A1 (en) 1993-04-15
EP0535548A1 (en) 1993-04-07
ATE209035T1 (de) 2001-12-15
NO923858D0 (no) 1992-10-02

Similar Documents

Publication Publication Date Title
MX9205659A (es) Inhibidor del engrosamiento interno ateroesclerotico.
ATE114645T1 (de) Mevalonolaktone vom chinolin-typ.
MY110447A (en) New herbicides
MY131297A (en) Herbicides
IL104614A (en) 4-benzoylisoxazole derivatives and herbicidal compositions comprising them
DK0613618T3 (da) Fremgangsmåde til beskyttelse af nytteplanter mod herbicider med substituerede benzopyran- og tetrahydronaphthalenforbindelser
BR8305546A (pt) Processo para a preparacao de derivados substituidos de 1-hidroxietil-triazolilo, composicoes de protecao as plantas e fungicidas e processos para o combate a fungos, para a protecao de plantas e para a preparacao de composicoes
NZ331123A (en) 2-(benzo-1,4-oxathiin)- or (benzo-1,4-dithiin)-cyclohexane-1,3-diones and herbicidal compositions
ATE15198T1 (de) Blutdrucksenkende 1-substituierte spiro(piperidin-oxobenzoxazine).
FI943508A0 (fi) Pyridiinikarboksimidamidiyhdisteet ja niiden käyttö
DK0411394T3 (da) Imidazoquinolon-derivater
ATE147376T1 (de) Heterocyclische derivate
DK0479175T3 (da) Pradimicinderivater
FI853907L (fi) Mellanprodukter foer framstaellning av 16-fenoxi- och 16-substituerade fenoxi-prostatriensyraderivat.
AU4776399A (en) Benflumetol derivatives, intermediates thereof and their use against parasiticalprotozoa and trematodes
GB9324871D0 (en) Novel compounds
JPS5350195A (en) Beta-lactam compounds
JPS57142915A (en) Antiphlogistic agent
ES2100998T3 (es) Composiciones farmaceuticas que contienen derivados de triazol para administracion rectal.